Cardea

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. The company specializes in graphene-based digital biosensor technology, which utilizes biocompatible graphene to convert biological signals into real-time data. Cardea's product offerings include the AGILE R100, a novel assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Additionally, the company is working on diagnostic tests for Lyme disease and the body’s immune response. By employing proprietary biology-gated transistors, Cardea enables precise analysis of biomolecules, facilitating applications in lead optimization, antibody characterization, and biomolecular analysis of various compounds. The company aims to enhance diagnostic processes, making them faster, easier, and more cost-effective, thereby serving the life sciences and healthcare sectors effectively. Founded in 2013, Cardea Bio was previously known as Nanomedical Diagnostics, Inc. before changing its name in September 2020.